Skip to main content
AAN.com
article
May 1, 1995

Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia

May 1995 issue
45 (5) 947-950

Abstract

Article abstract—We evaluated the neuropsychological and personality profiles of 25 patients with chronic myeloge-nous leukemia treated with interferon alfa (IFN-α). This group of persons performed well below expectation on tests of cognitive speed, verbal memory, and executive functions. Personality changes included depression, increased somatic concern, and stress reactions. A control group of leukemia patients not treated with IFN-α had significantly better cognitive speed and mood. The pattern of cognitive and personality changes in patients receiving IFN-α is highly suggestive of frontal-subcortical brain dysfunction.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 45Number 5May 1995
Pages: 947-950
PubMed: 7746412

Publication History

Published online: May 1, 1995
Published in print: May 1995

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

M. A. Pavol, MA
From the Departments of Neuro-Oncology (Drs. Meyers and Valentine, and M.A. Pavol, J.L. Rexer, and P.J. Mattis) and Clinical Immunology and Biologic Therapy (Dr. Talpaz), The University of Texas M.D. Anderson Cancer Center, Houston, TX.
C. A. Meyers, PhD
From the Departments of Neuro-Oncology (Drs. Meyers and Valentine, and M.A. Pavol, J.L. Rexer, and P.J. Mattis) and Clinical Immunology and Biologic Therapy (Dr. Talpaz), The University of Texas M.D. Anderson Cancer Center, Houston, TX.
J. L. Rexer, BS
From the Departments of Neuro-Oncology (Drs. Meyers and Valentine, and M.A. Pavol, J.L. Rexer, and P.J. Mattis) and Clinical Immunology and Biologic Therapy (Dr. Talpaz), The University of Texas M.D. Anderson Cancer Center, Houston, TX.
A. D. Valentine, MD
From the Departments of Neuro-Oncology (Drs. Meyers and Valentine, and M.A. Pavol, J.L. Rexer, and P.J. Mattis) and Clinical Immunology and Biologic Therapy (Dr. Talpaz), The University of Texas M.D. Anderson Cancer Center, Houston, TX.
P. J. Mattis, MA
From the Departments of Neuro-Oncology (Drs. Meyers and Valentine, and M.A. Pavol, J.L. Rexer, and P.J. Mattis) and Clinical Immunology and Biologic Therapy (Dr. Talpaz), The University of Texas M.D. Anderson Cancer Center, Houston, TX.
M. Talpaz, MD
From the Departments of Neuro-Oncology (Drs. Meyers and Valentine, and M.A. Pavol, J.L. Rexer, and P.J. Mattis) and Clinical Immunology and Biologic Therapy (Dr. Talpaz), The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Interferon therapy and its association with depressive disorders – A review, Frontiers in Immunology, 14, (2023).https://doi.org/10.3389/fimmu.2023.1048592
    Crossref
  2. Major depression during interferon-α treatment: vulnerability and prevention, Dialogues in Clinical Neuroscience, 11, 4, (417-425), (2022).https://doi.org/10.31887/DCNS.2009.11.4/felotrich
    Crossref
  3. Neurocognitive Changes in Chronic Hepatitis C Patients Receiving Combination Therapy of Interferon and Ribavirin: A Systematic Review, Current Drug Therapy, 17, 5, (349-358), (2022).https://doi.org/10.2174/1574885517666220617124629
    Crossref
  4. Neurological complications of systemic cancer and antineoplastic therapy, Neurological Complications of Systemic Cancer and Antineoplastic Therapy, (479-500), (2022).https://doi.org/10.1016/B978-0-12-821976-8.00015-3
    Crossref
  5. Major Depressive Disorder and gut microbiota – Association not causation. A scoping review, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 106, (110111), (2021).https://doi.org/10.1016/j.pnpbp.2020.110111
    Crossref
  6. Centrally Acting Angiotensin-Converting Enzyme Inhibitor Suppresses Type I Interferon Responses and Decreases Inflammation in the Periphery and the CNS in Lupus-Prone Mice, Frontiers in Immunology, 11, (2020).https://doi.org/10.3389/fimmu.2020.573677
    Crossref
  7. A pivotal role for Interferon-α receptor-1 in neuronal injury induced by HIV-1, Journal of Neuroinflammation, 17, 1, (2020).https://doi.org/10.1186/s12974-020-01894-2
    Crossref
  8. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNα): results from a prospective study, European Psychiatry, 21, 3, (204-210), (2020).https://doi.org/10.1016/j.eurpsy.2004.09.030
    Crossref
  9. C‐reactive protein, delirium, and other psychological symptoms among patients with advanced cancer, JCSM Clinical Reports, 5, 2, (42-51), (2020).https://doi.org/10.1002/crt2.12
    Crossref
  10. The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation, Neuroscience & Biobehavioral Reviews, 94, (219-237), (2018).https://doi.org/10.1016/j.neubiorev.2018.09.006
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share